TaiGen Biotech Eyes Pneumonia Antibiotic On China's Market By Year End
This article was originally published in PharmAsia News
TaiGen Biotechnology said China trials of its Taigexyn (nemonoxacin) pneumonia antibiotic are running smoothly and it estimates a $1.6 million market value in China by the end of the year.
You may also be interested in...
A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.